Related Experiment Videos

Aplastic Anemia, Pediatric Aspects

Alter1

  • 1Division of Pediatric Hematology/Oncology, The University of Texas Medical Branch at Galveston, Galveston, Texas, 77555-0361, USA.

The Oncologist
|January 1, 1996
PubMed

Insights

Inherited bone marrow failure syndromes (BMFs) are genetic disorders causing aplastic anemia, leukemia, and cancers. Early diagnosis and treatments like bone marrow transplantation are crucial for managing these conditions.

Area of Science:

  • Hematology
  • Genetics
  • Oncology

Background:

  • Inherited bone marrow failure syndromes (BMFs) account for a significant portion of aplastic anemia cases in children and adults.
  • Fanconi's anemia (FA) is the most common BMF, characterized by DNA repair defects, birth defects, and increased cancer risk.
  • Other BMFs include Dyskeratosis congenita (DC), Shwachman-Diamond syndrome, amegakaryocytic thrombocytopenia, Diamond-Blackfan anemia (DBA), and Kostmann's syndrome (KS).

Purpose of the Study:

  • To review the spectrum of inherited bone marrow failure syndromes.
  • To highlight the clinical manifestations, genetic basis, and management strategies for various BMFs.
  • To emphasize the association between BMFs and an increased risk of malignancy.

Main Methods:

  • Review of existing literature on inherited bone marrow failure syndromes.
  • Summarization of key features, diagnostic criteria, and treatment options for common BMFs.
  • Discussion of genetic underpinnings and emerging therapies such as gene therapy.

Main Results:

  • BMFs present with diverse combinations of marrow failure, cytopenias, and premalignant conditions.
  • Fanconi's anemia, Dyskeratosis congenita, and Shwachman-Diamond syndrome are associated with a high risk of leukemia and other cancers.
  • Specific genetic defects have been identified for several BMFs, enabling carrier identification and potential gene therapy approaches.

Conclusions:

  • Inherited bone marrow failure syndromes represent a heterogeneous group of genetic disorders with significant clinical implications, including hematologic abnormalities and increased cancer predisposition.
  • Advances in genetic understanding are paving the way for improved diagnostics, carrier screening, and novel therapeutic interventions, including gene therapy.
  • Bone marrow transplantation, androgens, and hematopoietic growth factors remain cornerstone treatments for managing BMFs and their complications.

Related Concept Videos